Skip to main content
. 2017 Mar 4;143(6):961–970. doi: 10.1007/s00432-017-2365-y

Fig. 1.

Fig. 1

Representative images of the immunohistochemistry results for cubilin from primary renal cell carcinomas, from patients later treated for metastatic disease with sunitinib or sorafenib in the first- or second-line setting, demonstrating negative (a), incomplete (b) and complete (c) membranous staining in tumor cells and normal kidney (d). Magnification ×200